PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy.

Kien Thiam TanChun-Nan YehYu-Chan ChangJen-Hao ChengWen-Liang FangYi-Chen YehYu-Chao WangDennis Shin-Shian HsuChiao-En WuJiun-I LaiPeter Mu-Hsin ChangMing-Han ChenMeng-Lun LuShu-Jen ChenYee ChaoMichael HsiaoMing-Huang Chen

Published in: Journal for immunotherapy of cancer (2021)

PRKDC is not only a predictive biomarker but also a drug target for immune checkpoint inhibitors.

Keyphrases

dna damage
cell cycle
adverse drug
drug induced
emergency department
oxidative stress
cell proliferation